Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study

W. A. Knight, Robert B Livingston, J. Costanzi, C. Fabian

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

One hundred and nine patients with advanced malignancy, refractory to conventional therapy, were treated with a weekly schedule of methyl-GAG. Ninety-one patients (83%) were less than fully ambulatory. Sixty-five patients were fully evaluable for response. There were two complete and nine partial responses. An additional nine patients had objective tumor regression and were classified as improved. The median duration of response was 5 months. Toxic effects were primarily mucositis (17 patients) and nausea and vomiting (14 patients). Sixty seven patients had no manifestations of drug toxicity. responses observed in a wide variety of solid tumors warrant further clinical trials.

Original languageEnglish (US)
Pages (from-to)1933-1937
Number of pages5
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - 1979
Externally publishedYes

Fingerprint

Neoplasms
Mucositis
Poisons
Drug-Related Side Effects and Adverse Reactions
Nausea
Vomiting
Appointments and Schedules
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Knight, W. A., Livingston, R. B., Costanzi, J., & Fabian, C. (1979). Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study. Cancer Treatment Reports, 63(11-12), 1933-1937.

Phase I-II trial of methyl-GAG : A Southwest Oncology Group pilot study. / Knight, W. A.; Livingston, Robert B; Costanzi, J.; Fabian, C.

In: Cancer Treatment Reports, Vol. 63, No. 11-12, 1979, p. 1933-1937.

Research output: Contribution to journalArticle

Knight, WA, Livingston, RB, Costanzi, J & Fabian, C 1979, 'Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study', Cancer Treatment Reports, vol. 63, no. 11-12, pp. 1933-1937.
Knight, W. A. ; Livingston, Robert B ; Costanzi, J. ; Fabian, C. / Phase I-II trial of methyl-GAG : A Southwest Oncology Group pilot study. In: Cancer Treatment Reports. 1979 ; Vol. 63, No. 11-12. pp. 1933-1937.
@article{3b329106a28b4efeb343e61999cd50f5,
title = "Phase I-II trial of methyl-GAG: A Southwest Oncology Group pilot study",
abstract = "One hundred and nine patients with advanced malignancy, refractory to conventional therapy, were treated with a weekly schedule of methyl-GAG. Ninety-one patients (83{\%}) were less than fully ambulatory. Sixty-five patients were fully evaluable for response. There were two complete and nine partial responses. An additional nine patients had objective tumor regression and were classified as improved. The median duration of response was 5 months. Toxic effects were primarily mucositis (17 patients) and nausea and vomiting (14 patients). Sixty seven patients had no manifestations of drug toxicity. responses observed in a wide variety of solid tumors warrant further clinical trials.",
author = "Knight, {W. A.} and Livingston, {Robert B} and J. Costanzi and C. Fabian",
year = "1979",
language = "English (US)",
volume = "63",
pages = "1933--1937",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11-12",

}

TY - JOUR

T1 - Phase I-II trial of methyl-GAG

T2 - A Southwest Oncology Group pilot study

AU - Knight, W. A.

AU - Livingston, Robert B

AU - Costanzi, J.

AU - Fabian, C.

PY - 1979

Y1 - 1979

N2 - One hundred and nine patients with advanced malignancy, refractory to conventional therapy, were treated with a weekly schedule of methyl-GAG. Ninety-one patients (83%) were less than fully ambulatory. Sixty-five patients were fully evaluable for response. There were two complete and nine partial responses. An additional nine patients had objective tumor regression and were classified as improved. The median duration of response was 5 months. Toxic effects were primarily mucositis (17 patients) and nausea and vomiting (14 patients). Sixty seven patients had no manifestations of drug toxicity. responses observed in a wide variety of solid tumors warrant further clinical trials.

AB - One hundred and nine patients with advanced malignancy, refractory to conventional therapy, were treated with a weekly schedule of methyl-GAG. Ninety-one patients (83%) were less than fully ambulatory. Sixty-five patients were fully evaluable for response. There were two complete and nine partial responses. An additional nine patients had objective tumor regression and were classified as improved. The median duration of response was 5 months. Toxic effects were primarily mucositis (17 patients) and nausea and vomiting (14 patients). Sixty seven patients had no manifestations of drug toxicity. responses observed in a wide variety of solid tumors warrant further clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0018628007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018628007&partnerID=8YFLogxK

M3 - Article

C2 - 526927

AN - SCOPUS:0018628007

VL - 63

SP - 1933

EP - 1937

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11-12

ER -